TG Therapeutics, Inc. (Nasdaq: TGTX) announced on October 12, 2026, the publication of a peer-reviewed five-year indirect comparison associating BRIUMVI (ublituximab-xiiy) with a lower risk of confirmed disability progression than ocrelizumab and ofatumumab in patients with relapsing multiple sclerosis. Published in Multiple Sclerosis and Related Disorders, the analysis reported a 44% lower modeled hazard of 24-week confirmed disability progression versus ocrelizumab and a 49% lower hazard versus ofatumumab, although these estimates were derived from separate clinical trials rather than a randomized head-to-head comparison.
The findings provide additional comparative evidence for BRIUMVI, an approved anti-CD20 therapy competing with established multiple sclerosis treatments marketed by Roche and Novartis. Investigators used a matching-adjusted indirect comparison to account for selected differences between patient populations, drawing on five-year follow-up data from pivotal studies and their extensions. The statistical approach produced favorable disability progression estimates for ublituximab, but it cannot eliminate every difference in trial design, patient characteristics or subsequent treatment exposure.
The publication arrives as TG Therapeutics expands an increasingly substantial commercial franchise. BRIUMVI generated $227.7 million in United States net product revenue during the second quarter of 2026, approximately 64% above the corresponding period of 2025. With the company targeting between $890 million and $905 million in full-year United States BRIUMVI sales, evidence supporting long-term treatment outcomes has commercial relevance beyond the immediate clinical publication.
The central question is how much confidence neurologists should place in favorable statistical comparisons when the therapies were never randomly assigned against each other in the same study. The latest results strengthen the rationale for further comparative investigation, particularly around disability accumulation, but they do not replace the direct evidence required to establish that one approved anti-CD20 medicine is clinically superior to another.
What do the five-year BRIUMVI results reveal about disability progression versus ocrelizumab and ofatumumab?
The strongest finding concerns 24-week confirmed disability progression, commonly abbreviated as CDP24. This endpoint measures sustained worsening of neurological disability, typically assessed using the Expanded Disability Status Scale, with the deterioration confirmed for at least 24 weeks. It is an important outcome in multiple sclerosis because preventing accumulated disability is a central objective of long-term disease-modifying treatment.
The published analysis estimated a hazard ratio of 0.560 for BRIUMVI compared with ocrelizumab, with a 95% confidence interval of 0.380 to 0.826. Against ofatumumab, the estimated hazard ratio was 0.509, with a confidence interval of 0.350 to 0.741. These values correspond to approximately 44% and 49% lower modeled hazards of confirmed disability progression, respectively, within the adjusted indirect comparisons.
The estimated cumulative incidence of CDP24 at 240 weeks was 9.3% with BRIUMVI versus 16.1% with ocrelizumab in one comparison. In the separate ofatumumab analysis, the corresponding estimates were 9.4% and 17.9%. The small difference between the two BRIUMVI estimates reflects separate statistical adjustments to align its original patient data with each comparator population.
These figures appear clinically interesting because they concern disability accumulation rather than relapse frequency alone. However, the estimated differences must not be interpreted as directly observed treatment effects from randomized groups receiving competing anti-CD20 medicines. They are model-based comparisons assembled from separate clinical development programmes, and their validity depends on assumptions about comparability between those programmes.
The study also examined restricted mean survival time, an approach measuring average time without confirmed disability progression over a defined observation period. BRIUMVI was associated with an estimated 8.1 additional progression-free weeks compared with ocrelizumab and 13.1 additional weeks compared with ofatumumab over 240 weeks. The respective confidence intervals were 2.3 to 14.1 weeks and 6.7 to 19.3 weeks.
These results provide a different statistical perspective on the disability findings, but they should not be interpreted as patients individually gaining a guaranteed additional period without progression. The estimates describe modeled average differences between adjusted populations. Their usefulness depends on whether the underlying assumptions adequately account for differences between the studies.
How does matching-adjusted indirect comparison work, and why can it not establish BRIUMVI superiority?
The investigators used an unanchored matching-adjusted indirect comparison, or MAIC, to evaluate long-term outcomes across three separate anti-CD20 clinical development programmes. Individual patient data from 545 BRIUMVI-treated participants in the Phase 3 ULTIMATE I and ULTIMATE II studies and their open-label extension were reweighted to resemble the published baseline characteristics of patients enrolled in other trials. The comparator programmes were OPERA I and II for ocrelizumab and ASCLEPIOS I and II for ofatumumab.
The adjustment considered available baseline characteristics including age, sex, initial disability score, magnetic resonance imaging disease activity, previous relapses and time since diagnosis. Statistical weighting assigns different importance to participants in the BRIUMVI dataset so that the resulting population more closely resembles each comparator trial population. The objective is to reduce observable demographic and clinical differences that could otherwise distort comparisons.
The researchers also relied on published long-term outcomes from the comparator programmes, reconstructing patient-level time-to-event information where required. This adds another analytical assumption because reconstructed data cannot necessarily reproduce every feature of the original patient records. An indirect comparison therefore differs fundamentally from a trial in which patients are randomly assigned to receive BRIUMVI, ocrelizumab or ofatumumab under the same protocol.
The absence of a shared randomized comparator is particularly consequential. Although the original pivotal trials involved randomized treatment assignments, they used different active comparators and were conducted in separate development programmes. The five-year MAIC cannot preserve the protection against confounding that randomization provides within an individual trial.
Unmeasured differences may remain even after observed characteristics have been balanced. These could include disease severity not fully captured by reported variables, previous treatment exposure, differences in disability assessment, extension-study retention and evolving clinical practices. Such differences are particularly relevant when analyzing disability outcomes over several years, because long-term follow-up may be influenced by treatment discontinuation and participant selection.
The investigators explicitly recognized these methodological limitations, describing the findings as exploratory and requiring confirmation through direct comparative studies or robust real-world evidence. The publication was funded by Neuraxpharm, TG Therapeutics’ European BRIUMVI commercialization partner. Its peer-reviewed status strengthens the transparency and scientific scrutiny of the analysis, but publication does not remove the inherent limitations of an unanchored comparison.
How did BRIUMVI perform on annualized relapse rates during five years of treatment?
The analysis also examined annualized relapse rate, which measures the average number of confirmed multiple sclerosis relapses per patient-year. Relapses remain clinically important because they can produce new neurological symptoms, require treatment and contribute to disability. However, reducing relapse frequency and preventing long-term disability accumulation are related but distinct clinical objectives.
In the population statistically adjusted to the ocrelizumab trials, BRIUMVI’s annualized relapse rate declined from 0.118 during the first treatment year to 0.032 during the fifth year. In the separately adjusted ofatumumab comparison, the corresponding rates declined from 0.116 to 0.030. These figures indicate consistently low modeled relapse activity among BRIUMVI-treated participants over the observation period.
TG Therapeutics highlighted favorable relapse outcomes compared with the comparator therapies, particularly ocrelizumab. However, the disclosed headline figures largely describe the annualized relapse rates within the adjusted BRIUMVI populations and should not be interpreted as proof of superiority against either competing medicine. The publication’s comparative conclusions remain exploratory for the same methodological reasons affecting the disability analysis.
The results are supported by an earlier five-year ULTIMATE extension analysis published in JAMA Neurology in February 2026. That investigation reported annualized relapse rates of 0.053, 0.032 and 0.020 during years three, four and five among participants who continued ublituximab from the original randomized treatment period. These are unadjusted extension-study observations from a defined treatment cohort, rather than the reweighted rates reported in the new comparison.
The extension study also found that participants who switched from teriflunomide to ublituximab experienced a substantial reduction in relapse activity after switching. Their annualized relapse rate declined from 0.182 before the switch to 0.076 during the first subsequent year, with further reductions reported during later follow-up. This provides evidence of sustained treatment activity within the ULTIMATE programme, although the extension phase was no longer a randomized comparison between continuing therapies.
Taken together, the findings strengthen evidence that BRIUMVI can maintain low relapse activity during prolonged treatment. What they do not establish is that its relapse-suppressing effect is necessarily greater than that of ocrelizumab or ofatumumab under equivalent clinical conditions.
What do the original ULTIMATE trials establish about long-term BRIUMVI efficacy?
BRIUMVI received its original United States approval in December 2022 following the Phase 3 ULTIMATE I and ULTIMATE II studies. Both were randomized, double-blind, active-controlled trials comparing ublituximab with teriflunomide over 96 weeks. Across the programmes, 1,094 patients with relapsing multiple sclerosis were enrolled.
The studies demonstrated that ublituximab significantly reduced annualized relapse rates compared with teriflunomide. They also reported fewer active magnetic resonance imaging lesions, supporting the medicine’s ability to suppress inflammatory disease activity. However, the pivotal studies did not establish statistically significant superiority over teriflunomide for confirmed disability progression, an important distinction when interpreting later long-term findings.
The open-label extension subsequently evaluated participants continuing ublituximab and those switching from teriflunomide to ublituximab. Of 985 participants completing the original studies, 851 entered the extension. More than 70% of participants in each extension treatment group remained on treatment at the fifth-year assessment cutoff.
At five years, the estimated proportion experiencing 24-week confirmed disability progression was 8.0% among participants who received continuous ublituximab, compared with 14.3% among those who initially received teriflunomide before switching. The difference was statistically significant in the reported extension analysis. However, extension participants represent a selected population, and the comparison was influenced by the original treatment assignment followed by a nonrandomized extension period.
This provides useful context for the new MAIC findings. The original trials establish efficacy against teriflunomide, while the long-term extension provides additional evidence on sustained disease control and treatment exposure. The latest publication attempts to extend comparative interpretation to other anti-CD20 therapies through statistical modeling, rather than producing new randomized treatment evidence.
Why do safety and administration differences remain important when comparing anti-CD20 therapies?
BRIUMVI, ocrelizumab and ofatumumab all target CD20-expressing B cells, but they differ in molecular structure, formulation and administration. BRIUMVI is a glycoengineered monoclonal antibody designed to enhance antibody-dependent cellular cytotoxicity through modifications to its antibody structure. These pharmacological differences provide a scientific rationale for investigating comparative outcomes, but they do not independently establish superior clinical efficacy.
BRIUMVI is administered intravenously, with an initial 150 mg infusion followed by 450 mg two weeks later and maintenance infusions every 24 weeks thereafter. Its approved infusion schedule permits subsequent maintenance administrations over approximately one hour. The relatively infrequent maintenance schedule may be attractive in certain treatment settings, although infusion-center access and premedication requirements remain relevant.
The competitive environment also includes convenient administration options for established alternatives. Novartis AG markets Kesimpta, the ofatumumab product administered by subcutaneous injection, with monthly maintenance dosing following its initial loading schedule. Roche’s ocrelizumab franchise includes intravenous Ocrevus and the United States-approved Ocrevus Zunovo formulation, which can be administered subcutaneously by a healthcare professional approximately every six months.
These differences may influence treatment selection independently of the indirect efficacy estimates. Patients and healthcare providers may consider dosing frequency, administration location, treatment time, monitoring requirements and personal circumstances alongside efficacy and safety evidence. A favorable modeled disability outcome does not establish that one treatment is preferable across all these dimensions.
Safety is equally important because sustained B-cell depletion can affect immune function. BRIUMVI’s prescribing information identifies risks including infusion reactions, infections, hepatitis B reactivation, progressive multifocal leukoencephalopathy, reduced immunoglobulin concentrations and clinically significant liver injury. The original multiple sclerosis trials reported infusion reactions in 48% of treated participants and serious infections in approximately 5%, compared with 3% among teriflunomide-treated patients.
Long-term ULTIMATE follow-up did not identify new safety signals, but the October indirect comparison was focused on relapse activity and confirmed disability progression. It does not establish that BRIUMVI has fewer serious adverse events, lower infection risk or a better overall safety profile than ocrelizumab or ofatumumab. Those questions require appropriately designed comparative safety assessments.
How could the published findings influence TG Therapeutics’ BRIUMVI commercial growth?
BRIUMVI has become the central commercial product for TG Therapeutics, with United States net sales of $227.7 million in the second quarter of 2026. That represented approximately 64% growth compared with the same period in 2025. Total company revenue reached $240.3 million, including product supply revenue associated with its international commercialization partner and other licensing-related income.
The company increased its full-year 2026 United States BRIUMVI net product revenue target to between $890 million and $905 million. It also raised its total global revenue target to approximately $950 million. These forecasts demonstrate management’s expectations for continued commercial expansion, although the October publication does not itself establish incremental revenue beyond that guidance.
TG Therapeutics reported approximately $612.3 million in cash, cash equivalents and investment securities at June 30, 2026. It also recorded second-quarter net income of $7.8 million, compared with $28.2 million a year earlier, reflecting increased operating investment. Research and development expenditure was affected by manufacturing-related costs associated with its subcutaneous BRIUMVI programme and secondary manufacturing preparations.
The company’s commercial strategy depends partly on establishing BRIUMVI as a competitive treatment within the established anti-CD20 multiple sclerosis market. Roche and Novartis have extensive commercial infrastructure, established clinical evidence and existing relationships with neurologists and healthcare systems. TG Therapeutics must therefore compete through a combination of treatment outcomes, administration characteristics, physician experience, access and reimbursement.
The new publication gives the company additional material for scientific engagement concerning long-term disability outcomes. However, exploratory indirect comparisons are not equivalent to regulatory-approved superiority claims and should not be treated as evidence that physicians or payers will necessarily prefer BRIUMVI. Their commercial contribution will depend on how specialists evaluate the analysis alongside the broader evidence available for competing treatments.
Neuraxpharm’s involvement also has international significance. Under its commercialization agreement with TG Therapeutics, Neuraxpharm holds rights across specified territories outside North America and certain previously partnered Asian countries. The agreement includes product supply arrangements and tiered royalties, making continued international development commercially relevant to TG Therapeutics without equating partner sales directly with its own recognized product revenue.
Could BRIUMVI’s next clinical studies strengthen its competitive position beyond the five-year analysis?
TG Therapeutics is pursuing additional development work intended to improve BRIUMVI’s treatment profile and expand its commercial opportunity. One programme involves the Phase 3 ENHANCE study, which evaluated a simplified intravenous initiation regimen combining the first two doses into a single initial administration. The company previously reported positive results, with additional findings scheduled for presentation at the October 2026 multiple sclerosis meeting in Toronto.
A separate Phase 3 programme is evaluating a subcutaneous formulation of ublituximab. TG Therapeutics has reported encouraging Phase 1 pharmacokinetic and tolerability findings and is investigating a quarterly subcutaneous maintenance regimen. Management expects topline Phase 3 results around the end of 2026 or the first quarter of 2027, although that timing remains prospective.
The subcutaneous programme is particularly relevant because administration convenience has become an important competitive consideration in multiple sclerosis treatment. An approved formulation offering less frequent injections could give TG Therapeutics another option alongside its intravenous product. However, the investigational subcutaneous formulation is not currently authorized, and the ongoing Phase 3 programme must establish the evidence required for regulatory review.
Beyond BRIUMVI, the company is developing azer-cel, an investigational allogeneic CD19-directed cell therapy, including research in progressive multiple sclerosis. Initial results are scheduled for presentation during the Toronto meeting later in October. This represents a separate therapeutic strategy and should not be confused with the clinical evidence or approved indications for ublituximab.
The company therefore has several potential development milestones, but they carry different clinical and regulatory implications. Simplifying intravenous administration concerns the established BRIUMVI product, subcutaneous development seeks an alternative formulation, and azer-cel involves a distinct investigational treatment. Their future commercial value cannot be inferred from the favorable findings of the five-year indirect comparison.
What does the publication mean for TG Therapeutics stock and investor sentiment?
TG Therapeutics shares closed at $55.37 on Friday, October 9, 2026, rising 3.81% during the session. The stock had traded between approximately $51.34 and $58.92 during the preceding 30-day period, reflecting considerable movement in the weeks approaching the latest clinical publication. Because the company released its announcement on October 12, the preceding Friday’s gain cannot be attributed to the new disclosure.
The latest publication is best understood as an evidence-strengthening development for an approved commercial franchise rather than a regulatory approval, a new indication or a completed clinical trial comparing all three medicines. It may reinforce positive sentiment among investors who consider long-term disability outcomes important to BRIUMVI’s market positioning. Nevertheless, the absence of randomized head-to-head evidence limits the extent to which the findings can support assumptions about future market share.
The financial context gives investors more concrete measures against which to assess the company’s progress. Quarterly BRIUMVI sales growth, updated annual guidance and development spending offer direct information about operating performance. By comparison, the indirect analysis provides a possible competitive narrative whose eventual commercial impact remains uncertain.
For investors evaluating TG Therapeutics, the next significant indicators will include third-quarter sales performance, progress toward the full-year BRIUMVI revenue target and updates from the ENHANCE and subcutaneous development programmes. These developments can provide measurable financial or regulatory evidence beyond the statistical comparisons reported in the new publication.
What further evidence is needed to establish whether BRIUMVI is clinically better than competing anti-CD20 therapies?
The new analysis provides a scientifically useful hypothesis: long-term BRIUMVI treatment may be associated with favorable disability outcomes relative to ocrelizumab and ofatumumab after adjustment for selected patient characteristics. The reported hazard ratios and restricted mean survival time differences are sufficiently notable to justify further investigation. However, the distinction between association and demonstrated comparative efficacy remains fundamental.
A randomized head-to-head trial would provide stronger evidence because patients could be allocated to competing treatments under a shared protocol, with consistent eligibility criteria and endpoint assessments. Such a study would better control for confounding and enable direct evaluation of disability progression, relapse activity and safety. It would also require substantial time and resources, particularly because disability events may accumulate slowly under modern high-efficacy treatments.
Well-designed real-world comparative research may provide another route to strengthening the evidence. Large patient registries and healthcare datasets can potentially compare treatment outcomes across routine clinical populations, although observational studies must address differences in treatment selection, disease severity, follow-up and missing information. Statistical adjustment remains useful in that setting, but it does not eliminate every possible source of bias.
The October publication adds a new dimension to the BRIUMVI evidence package because it examines disability progression across five years rather than relying exclusively on short-term relapse suppression. Its findings are favorable to ublituximab, and the peer-reviewed methodology makes the assumptions open to scientific scrutiny. Yet the study’s unanchored design, dependence on published comparator outcomes and inability to account for unmeasured differences prevent it from establishing definitive superiority.
For TG Therapeutics, the commercial challenge is to convert a growing body of long-term efficacy evidence into durable physician confidence while continuing to expand access and improve administration options. BRIUMVI already has regulatory authorization, substantial quarterly sales and evidence of sustained disease control from its own clinical development programme. The unanswered question is whether its apparent advantage in modeled disability progression would persist when tested against ocrelizumab and ofatumumab under genuinely comparable clinical conditions.
